Fujian Cancer Hospital

This study is testing whether combining two newer drugs, sacituzumab tirumotecan and QL1706, can help control advanced cervical cancer that has returned or spread after standard chemotherapy. It will enroll about 89 women to see how well the combination shrinks tumors and how saf…

This study is testing whether a new combination of two immunotherapy drugs (iparomlimab and tuvonralimab) plus standard chemotherapy can shrink tumors in patients with locally advanced cervical cancer before they have surgery. The goal is to see if this preoperative treatment lea…

This study is testing a new combination treatment for people whose rectal cancer has spread to the liver. It combines a short, intense course of radiation with standard chemotherapy and a new type of immunotherapy drug (QL1706) that targets the immune system in two ways. The goal…

This study is testing if adding radiation therapy to standard immunotherapy helps patients with a specific type of advanced lung cancer live longer without their cancer getting worse after surgery. It will involve 60 adults who have had surgery but are at high risk of the cancer …

This study aims to see if adding a low-dose, continuous chemotherapy pill (capecitabine) to a standard two-drug treatment works better for controlling advanced breast cancer that has spread to internal organs like the liver or lungs. It will involve 258 women whose cancer is horm…